Literature DB >> 31469008

Multidrug resistance in anaerobes.

Lyudmila Boyanova1, Rumyana Markovska1, Ivan Mitov1.   

Abstract

Multidrug resistance (MDR) in anaerobes is not a well-known topic. Bacteroides fragilis group isolates have numerous resistance determinants such as multidrug efflux pumps, cfiA and nimB genes and activating insertion sequences, and some isolates exhibited extensive drug-resistant patterns. MDR rates in B. fragilis group were from 1.5 to >18% and up to >71% in cfiA and nimB positive isolates carrying insertion sequences. MDR was present in >1/2 of Clostridioides difficile isolates, most often in epidemic/hypervirulent strains and unusually high metronidazole or vancomycin resistance has been reported in single studies. MDR was found in Prevotella spp. (in ≤10% of isolates), Finegoldia magna, Veillonella spp. and Cutibacterium acnes. Resistance in the anaerobes tends to be less predictable and anaerobic microbiology is required in more laboratories. New hopes may be new antibiotics such as eravacycline, cadazolid, surotomycin, ridinilazol or C. difficile toxoid vaccines; however, more efforts are needed to track the MDR in anaerobes.

Entities:  

Keywords:  anaerobes; anaerobic cocci; mechanisms; multidrug resistance; prevalence; rates

Mesh:

Substances:

Year:  2019        PMID: 31469008     DOI: 10.2217/fmb-2019-0132

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  2 in total

1.  In-Silico Tool for Predicting, Scanning, and Designing Defensins.

Authors:  Dilraj Kaur; Sumeet Patiyal; Chakit Arora; Ritesh Singh; Gaurav Lodhi; Gajendra P S Raghava
Journal:  Front Immunol       Date:  2021-11-22       Impact factor: 7.561

2.  In Vitro Efficacy of Antibiotic Combinations with Carbapenems and Other Agents against Anaerobic Bacteria.

Authors:  Takumi Umemura; Mao Hagihara; Takeshi Mori; Hiroshige Mikamo
Journal:  Antibiotics (Basel)       Date:  2022-02-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.